Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders
in humans, partly because it is closely related to metabolic disorders of the liver with …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide. It is strongly associated with obesity, type 2 diabetes (T2DM), and other …

Non‐alcoholic fatty liver disease is comprised of either simple steatosis (non‐alcoholic fatty
liver) or a more advanced inflammatory and fibrogenic stage (non‐alcoholic steatohepatitis …

Nano-drug delivery strategies have been highlighted in cancer treatment, and much effort
has been made in the optimization of bioavailability, biocompatibility, pharmacokinetics …

Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

The liver is a critical system for metabolism in human beings, which plays an essential role
in an abundance of physiological processes and is vulnerable to endogenous or exogenous …

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the adult population
worldwide. This pathology can progress into end-stage liver disease with life-threatening …

Hypoxia is an important feature, which can upregulate the hypoxia‐inducible factor‐1α (HIF‐
1α) expression and promote the activation of hepatic stellate cells (HSCs), leading to liver …

In the past five decades, red blood cells (RBCs) have been extensively explored as drug
delivery systems due to their distinguishing potential in modulating the pharmacokinetic …

As a natural product with various biological activities, triptolide (TP) has been reported in
anti-inflammatory, anti-tumor and anti-autoimmune studies. However, the narrow therapeutic …